Preoperative Intravenous Ferric Carboxymaltose and Placebo in the Treatment of Patients Undergoing Cardiac Surgery (PREFER-CABG)
A Phase IV Double-blind, Randomised, Parallel Group Comparison of the Efficacy and Safety of Preoperative Intravenous Ferric Carboxymaltose and Placebo in the Treatment of Patients Undergoing Elective or Urgent Cardiac Surgery
Sponsor: Turku University Hospital
This PHASE4 trial investigates Aortic Aneurysm, Thoracic and Aortic Valve Stenosis and is currently ongoing. Turku University Hospital leads this study, which shows 8 recorded versions since 2018 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2024 — Jul 2024 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
May 2021 — Jan 2024 [monthly]
Recruiting PHASE4
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE4
▶ Show 3 earlier versions
-
Dec 2019 — Jan 2021 [monthly]
Recruiting PHASE4
-
Nov 2018 — Dec 2019 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Jul 2018 — Nov 2018 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Turku University Hospital
- Vifor Pharma
For direct contact, visit the study record on ClinicalTrials.gov .